Want to see CH:DAE full AI Analyst Report?
Top Page
Daetwyler Holding
(DAE)
Select Model
Select Model
Rating:52Neutral
Price Target:
CHF127.00
▼(-5.65% Downside)
Action:Reiterated
Date:08/06/26
The score is held back primarily by balance-sheet leverage and weak technical trend/momentum (price below all major moving averages with negative MACD). Offsetting these are consistently positive free cash flow and a 2025 top-line rebound, while valuation is neither clearly cheap nor extremely expensive given the higher P/E tempered by a moderate dividend yield.
Positive Factors
Specialized regulated-market capabilities
Daetwyler’s materials and manufacturing know-how support components where reliability, quality, and regulatory compliance matter. These requirements can create defensible customer relationships and reduce substitution risk, supporting durable demand across healthcare and selected industrial markets.
Negative Factors
Elevated balance-sheet leverage
Leverage remains materially higher than Daetwyler’s earlier history, limiting financial flexibility even after some debt reduction in 2025. Higher debt relative to equity can constrain investment choices and leave the company less able to absorb prolonged weakness in demand or profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized regulated-market capabilities
Daetwyler’s materials and manufacturing know-how support components where reliability, quality, and regulatory compliance matter. These requirements can create defensible customer relationships and reduce substitution risk, supporting durable demand across healthcare and selected industrial markets.
Read all positive factors
Daetwyler Holding (DAE) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.17B
Dividend Yield2.51%
Average Volume (3M)11.43K
Price to Earnings (P/E)26.4
Beta (1Y)0.58
Revenue Growth2.00%
EPS Growth170.40%
CountryCH
Employees7,823
SectorGeneral
Sector StrengthN/A
IndustryIndustrial - Distribution
Share Statistics
EPS (TTM)4.83
Shares Outstanding12,600,000
10 Day Avg. Volume14,709
30 Day Avg. Volume11,434
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)7.53
Price to Sales (P/S)2.53
P/FCF Ratio21.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF169.00Price Target Upside25.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)5.38
Revenue Forecast (FY)CHF1.16B
Daetwyler Holding Business Overview & Revenue Model
Company Description
Dätwyler Holding AG, established in 1915 and headquartered in Altdorf, Switzerland, operates as a subsidiary of Pema Holding AG. The company specializes in the global manufacturing and distribution of elastomer components for a variety of sectors,...
How the Company Makes Money
Daetwyler makes money primarily by selling manufactured components and systems to business customers (B2B), generating revenue from product shipments under supply agreements and recurring orders from customers that integrate Daetwyler parts into t...
Daetwyler Holding Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
46
Neutral
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.12B | 1.10B | 1.11B | 1.15B | 1.15B | 947.60M |
| Gross Profit | 271.40M | 257.90M | 238.30M | 240.20M | 255.20M | 247.60M |
| EBITDA | 192.90M | 188.70M | 144.10M | 187.20M | 224.30M | 225.50M |
| Net Income | 82.20M | 80.80M | 31.10M | 66.80M | 104.80M | 194.00M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 1.07B | 1.15B | 1.20B | 1.30B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 83.60M | 125.50M | 127.40M | 122.50M | 101.30M | 279.60M |
| Total Debt | 507.50M | 504.60M | 574.40M | 639.60M | 697.40M | 150.50M |
| Total Liabilities | 759.60M | 695.90M | 781.70M | 814.60M | 895.40M | 312.70M |
| Stockholders Equity | 326.20M | 369.40M | 368.50M | 386.20M | 403.60M | 948.30M |
Cash Flow | ||||||
| Free Cash Flow | 118.90M | 126.90M | 127.50M | 135.40M | 18.40M | 72.20M |
| Operating Cash Flow | 160.20M | 173.80M | 171.70M | 194.90M | 118.60M | 183.50M |
| Investing Cash Flow | -81.50M | -44.40M | -43.80M | -58.20M | -701.50M | -23.10M |
| Financing Cash Flow | -101.80M | -126.10M | -124.90M | -109.70M | 466.80M | -113.00M |
Daetwyler Holding Technical Analysis
Negative
134.60
Price Trends
133.47
Negative
146.12
Negative
151.04
Negative
Market Momentum
-2.29
Negative
37.67
Neutral
62.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:DAE, the sentiment is Negative. The current price of 134.6 is above the 20-day moving average (MA) of 127.86, above the 50-day MA of 133.47, and below the 200-day MA of 151.04, indicating a bearish trend. The MACD of -2.29 indicates Negative momentum. The RSI at 37.67 is Neutral, neither overbought nor oversold. The STOCH value of 62.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:DAE.
Daetwyler Holding Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | CHF264.45M | 9.61 | 11.74% | 3.72% | -1.24% | -11.13% | |
70 Outperform | CHF15.54B | 41.84 | ― | 1.03% | 2.24% | -5.84% | |
64 Neutral | CHF2.28B | 31.05 | 16.40% | 0.96% | 7.51% | -20.13% | |
64 Neutral | CHF4.73B | 22.10 | 28.54% | 1.22% | -2.39% | 154.37% | |
62 Neutral | CHF1.18B | 71.83 | ― | ― | 29.92% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | CHF2.17B | 26.42 | 23.63% | 2.51% | 2.00% | 170.40% |
* General Sector Average
CH:DAE
Daetwyler Holding
125.60
-10.84
-7.95%
CH:STMN
Straumann Holding AG
96.44
10.18
11.80%
CH:MOVE
Medacta Group SA
115.00
-29.68
-20.52%
CH:MIKN
Mikron Holding AG
16.00
-1.35
-7.78%
CH:YPSN
Ypsomed Holding AG
367.00
64.73
21.42%
CH:MED
Medartis Holding AG
86.00
-0.50
-0.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.